Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;188(4):488-493.
doi: 10.1111/bjh.16273. Epub 2019 Nov 6.

Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention

Dibyendu Dutta  1 , Amandeep Aujla  1 , Bettina M Knoll  2 , Seah H Lim  1   3
Affiliations
Free article
Review

Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention

Dibyendu Dutta et al. Br J Haematol. 2020 Feb.
Free article

Abstract

There is a large therapeutic gap in the treatment of sickle cell disease (SCD). Recent studies demonstrated the presence of pathophysiological and microbial changes in the intestine of patients with SCD. The intestinal microbes have also been found to regulate neutrophil ageing and possible basal activation of circulating neutrophils. Both aged and activated neutrophils are pivotal for the pathogenesis of vaso-occlusive crisis in SCD. In this paper, we will provide an overview of the intestinal pathophysiological and microbial changes in SCD. Based on these changes, we will propose therapeutic approaches that could be investigated for treating SCD.

Keywords: Sickle cell disease; intestinal injury; intestinal microbial changes; intestinal permeability; vaso-occlusive crisis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agbai, O. (1986) Anti-sickling effect of dietary thiocyanate in prophylactic control of sickle cell anemia. Journal of the National Medical Association, 78, 1053-1056.
    1. Ahmed, J., Kumar, A., Jafri, F., Batool, S., Knoll, B. & Lim, S.H. (2019) Low incidence of hospital-onset Clostridium difficile infection in sickle cell disease. New England Journal, Medicine, 380, 887-888.
    1. Arias, E., Rostron, B.L. & Tejada-Vera, B. (2010) United States life tables, 2005. National Vital Statistic Reports, 58, 1-132.
    1. Ataga, K.I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T.H., Knight-Madden, J., Alvarez, O.A. & Gordeuk, V.R. (2017) Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine, 376, 429-439.
    1. Bass, N.M., Mullen, K.D., Sanyal, A., Poordad, F., Neff, G., Leevy, C.B., Sigal, S., Sheikh, M.Y., Beavers, K. & Frederick, T. (2010) Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine, 362, 1071-1081.

Publication types

MeSH terms